Personalis, Inc. reported a significant decline in its financial performance for the second quarter of 2025, with total revenue decreasing by 24% to $17.2 million compared to $22.6 million in the same period last year. The company attributed this drop primarily to a $5.6 million decrease in revenue from its major customer, Natera, alongside a reduction in revenue from pharmaceutical tests and services. However, there was a notable increase in population sequencing revenue, which rose by 158% to $3.3 million, reflecting the company's ongoing partnership with the U.S. Department of Veterans Affairs' Million Veteran Program.

In terms of profitability, Personalis reported a net loss of $20.1 million for the second quarter, compared to a loss of $12.8 million in the prior year. The loss per share was $0.23, slightly improved from $0.24 in the same quarter of 2024. The company's total costs and expenses remained relatively stable, totaling $39 million, with selling, general, and administrative expenses increasing by 18% due to expanded marketing efforts related to its NeXT Personal Dx platform.

Operationally, Personalis has made strides in clinical adoption, delivering 3,478 clinical tests in the second quarter, marking a 59% increase from the previous quarter. The company has also expanded its collaboration with Tempus AI, adding colorectal cancer to its commercialization agreement, which is expected to enhance its market presence. The company continues to focus on building clinical evidence to support its products, having presented pivotal data at the recent American Society for Clinical Oncology Annual Meeting.

As of June 30, 2025, Personalis reported total assets of $258.7 million, down from $270.3 million at the end of 2024. The company had cash and cash equivalents of $53.4 million and short-term investments of $119.9 million. Despite the losses, Personalis anticipates that its current cash reserves, along with expected cash flow from operations, will be sufficient to meet its capital and operating needs for at least the next 12 months. The company is actively pursuing additional partnerships and reimbursement coverage to bolster its revenue streams moving forward.

About Personalis, Inc.

Personalis, Inc. develops and markets advanced cancer genomic tests and services for precision oncology, including liquid biopsy and tumor profiling. Its offerings support pharmaceutical research, biomarker discovery, and clinical decision-making. Serving global markets, the company emphasizes high-sensitivity technologies, clinical evidence, and strategic collaborations to enable personalized cancer therapies and improve patient outcomes. Its business model centers on high-quality genomic testing for healthcare providers and biopharmaceutical companies.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.